New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

New York Plastic Surgical Group (NYPS Group) and Deep Blue Med Spa (DBMS) are proud to announce that they have once again been recognized by Allergan Aesthetics as the #1 provider in New York State, marking the second consecutive year earning this distinction. In addition, the practices have been ranked Top 50 in the nation for 2026, placing them among an elite group of aesthetic providers across the United States.

This recognition reflects NYPS Group and Deep Blue Med Spa's continued leadership in aesthetic medicine and their longstanding commitment to delivering advanced, evidence-based treatments performed by highly trained medical professionals.

Allergan Aesthetics, an AbbVie company, develops and manufactures some of the most recognized brands in medical aesthetics, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers, Skinvive™, CoolSculpting®, CoolTone®, DiamondGlow®, and SkinMedica®, among others. Rankings are determined through the Allergan Partner Privileges program, which acknowledges practices based on their experience and volume of Allergan aesthetic products and treatments.

Earning the #1 ranking in New York for the second year in a row underscores the trust patients place in NYPS Group and Deep Blue Med Spa for injectable treatments, body contouring, and comprehensive aesthetic services. National Top 50 placement further distinguishes the practices as leaders in the field.

"This continued recognition from Allergan Aesthetics reflects the dedication of our surgeons, physician assistants, nurse practitioners, and aesthetic providers who prioritize patient safety, education, and natural-looking results," said NYPS Group President, Tommaso Addona, MD, FACS. "It is an honor and a privilege to serve our patients with advanced treatments backed by science and delivered with precision."

For patients, this designation signals a high level of experience with Allergan's portfolio of products and access to exclusive offerings and rewards through Allergan's programs. It also reflects ongoing investment in provider training, as multiple NYPS Group and Deep Blue Med Spa clinicians have been selected to serve as national Allergan Medical Institute (AMI) trainers, contributing to peer education across the country.

About New York Plastic Surgical Group and Deep Blue Med Spa
As the largest and longest-running private and academic plastic surgery practice in the United States, New York Plastic Surgical Group includes more than 20 experienced plastic surgeons and maintains over 10 offices throughout the metropolitan area. In addition to its surgical practice, NYPS Group operates Deep Blue Med Spa, which provides non-surgical aesthetic treatments in multiple New York locations. Together, the practices are known for clinical excellence, comprehensive patient care, and a commitment to advancing the field of aesthetic medicine through education and innovation.

About Allergan Aesthetics
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), develops, manufactures, and markets a portfolio of leading aesthetics brands and products worldwide. Its offerings include facial injectables, body contouring technologies, skin care, and more. Through ongoing research and innovation, Allergan Aesthetics remains committed to advancing science-based solutions in aesthetic medicine.

Attachment


Jeanine DiGennaro Director of Marketing & Communications (516) 629-3835 jdigennaro@nyplasticsurgical.com New York Plastic Surgical Group (516) 742-3404 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ABBV
The Conversation (0)
Health Canada Approves AbbVie's RINVOQ®  for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

- Approval is based on results from the Phase 3 SELECT-AXIS 2 pivotal clinical trial in which RINVOQ delivered rapid and meaningful disease control, meeting the primary endpoint of ASAS40 response at week 14 versus placebo 1 - RINVOQ is the first and only Janus Kinase (JAK) inhibitor approved to... Keep Reading...
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®

- Oral presentations highlight efficacy and safety outcomes from the upadacitinib (RINVOQ ® ) clinical trial program in adults with moderately to severely active Crohn's disease, and investigational use of linaclotide (LINZESS ® ) in treating functional constipation in pediatric patients aged 6... Keep Reading...
Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Announces Exclusive Global Licensing Agreement with Allergan Aesthetics

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") is pleased to announce it has entered into a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie company (NYSE: ABBV), pursuant to which Allergan Aesthetics will develop and commercialize topical skin... Keep Reading...
Seegnal

Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Company"), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced the formation of a dedicated Strategic Commercialization Team led by its Chief Executive Officer, and the... Keep Reading...
Dollar bills, pink and white pills in blister packs, and a nasal spray on a blue background.

Blackstone Raises Record US$6.3 Billion for Largest Life Sciences Fund

Blackstone (NYSE:BX) has raised US$6.3 billion for its latest life sciences fund, the largest private vehicle dedicated to the sector.The fund, Blackstone Life Sciences VI (BXLS VI), was oversubscribed and closed at its hard cap, about 40 percent larger than its predecessor, which raised US$4.6... Keep Reading...
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...

Interactive Chart

Latest Press Releases

Related News